Related Experiment Video
Updated: Sep 9, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
Himisha Beltran1, Jeremie Calais2, Louise Emmett3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Abstract:
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [177Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [177Lu]Lu-PSMA-617 and guide therapy decision-making. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [177Lu]Lu-PSMA-617 treatment for patients with mCRPC.
Insights
New biomarkers are needed to identify patients with metastatic castration-resistant prostate cancer who will best respond to prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). This helps optimize treatment selection and outcomes.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 offers a new treatment option for metastatic castration-resistant prostate cancer (mCRPC).
- However, not all patients achieve optimal response, and accurate response assessment remains challenging.
- Validated prognostic and predictive biomarkers for [177Lu]Lu-PSMA-617 are currently lacking in the mCRPC patient population.
Purpose of the Study:
- To review emerging clinical, molecular, and imaging biomarkers for [177Lu]Lu-PSMA-617 therapy in mCRPC.
- To assess the potential utility of these biomarkers in predicting treatment response and patient outcomes.
- To highlight the need for biomarker development to optimize patient selection and guide therapeutic decisions.
Main Methods:
- Comprehensive literature review of studies on biomarkers for [177Lu]Lu-PSMA-617 in mCRPC.
- Analysis of clinical, molecular, and imaging data related to treatment response and survival.
- Synthesis of current evidence on the prognostic and predictive value of identified biomarkers.
Main Results:
- Several emerging biomarkers across clinical, molecular, and imaging domains show promise.
- These biomarkers may help identify patients likely to benefit from [177Lu]Lu-PSMA-617 therapy.
- Further validation is required to establish their role in routine clinical practice.
Conclusions:
- There is a critical need for validated biomarkers to personalize [177Lu]Lu-PSMA-617 treatment in mCRPC.
- Biomarker discovery can improve patient selection, optimize therapeutic strategies, and enhance outcomes.
- Continued research into prognostic and predictive biomarkers is essential for advancing RLT in prostate cancer.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013